Harvard and Merck Team to Find Immuno-Oncology Targets

Harvard and Merck Team to Find Immuno-Oncology Targets »

  Check-point inhibitors and other immunotherapies have revolutionized the treatment of some cancers. But some patients do not respond at all – and others develop resistance to the drugs. Now Harvard University and Merck experts are teaming up to discover the reason why, down to the molecule and gene. The projected four-year undertaking will be…

Send this to a friend